准独特的配体结合域结构特征 降低DKK1在Y537SESR1突变乳腺癌细胞中的调节
K S Young1, G R Hancock1, E Fink1
1Department of Cancer Biology, Loyola University Chicago Stritch School of Medicine, Maywood, IL 50153.
Research square
|July 9, 2024
概括
一种新的选择性雌激素受体调节器 (SERM),T6I-29,在雌激素受体α (ERα) 突变乳腺癌中显示出抗增殖作用. 它降低了DKK1,这是内分泌抵抗性ER+乳腺癌的潜在治疗标.
科学领域:
- 在瘤学瘤学.
- 内分泌学 在内分泌学.
- 分子生物学分子生物学
背景情况:
- 内分泌疗法耐药性是乳腺癌治疗的一个主要挑战.
- 雌激素受体α (ERα) 的突变,特别是Y537S,驱动对选择性雌激素受体调节剂 (SERM) 和降解剂 (SERD) 的耐药性.
- 现有疗法在ERα突变患者中往往具有非持久的反应.
研究的目的:
- 综合评估新型SERM,T6I-29对携带Y537S ERα突变的乳腺癌细胞的活性.
- 阐明T6I-29疗效背后的分子机制.
- 确定内分泌抵抗性乳腺癌中潜在的新治疗点.
主要方法:
- 结构生物化学分析
- 在体外基于细胞的试验.
- 在体内临床前模型.
- 有关RNA测序的RNA测序
主要成果:
- T6I-29在Y537S ERα乳腺癌细胞中表现出显著的抗增殖活性.
- T6I-29治疗导致DKK1的新型下调,DKK1是一种具有致癌作用的糖蛋白.
- 与健康对照组相比,DKK1在ER+乳腺癌患者的血中被发现显著丰富.
结论:
- 新型SERM T6I-29对Y537S ERα突变乳腺癌表现出强大的抗癌活性.
- DKK1代表了内分泌抵抗性ER+乳腺癌的潜在治疗标和生物标志物.
- 这项研究强调了新型SERM和SERD在识别内分泌抵抗性乳腺癌的新疗法策略方面的潜力.
更多相关视频
08:11Characterization of Cell Membrane Extensions and Studying Their Roles in Cancer Cell Adhesion Dynamics
Published on: March 26, 2018
8.3K
09:07Detecting the Ligand-binding Domain Dimerization Activity of Estrogen Receptor Alpha Using the Mammalian Two-Hybrid Assay
Published on: December 19, 2018
6.4K
相关概念视频
01:15Receptor Downregulation in MVBs
2.0K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.0K
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K
01:20The JAK-STAT Signaling Pathway
8.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.8K
01:26Receptor Tyrosine Kinases
12.7K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
12.7K
01:22Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
2.2K
Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
2.2K
02:38Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K